Related Experiment Videos
Pilot evaluation of gabapentin for treating hot flashes
L Loprinzi1, Debra L Barton, Jeff A Sloan
1Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA. cloprinzi@mayo.edu
Mayo Clinic Proceedings
|November 21, 2002
Summary
Gabapentin shows promise in reducing hot flash frequency and severity. This pilot study suggests gabapentin is a viable alternative for managing hot flashes, especially for those avoiding hormonal therapy.
Area of Science:
- Pharmacology
- Clinical Trials
- Women's Health
Background:
- Hot flashes are a common symptom, often associated with menopause.
- Current treatments may have limitations or side effects.
- Alternative therapeutic options are needed for managing hot flashes.
Purpose of the Study:
- To evaluate the efficacy and tolerability of gabapentin for hot flash symptom relief.
- To gather preliminary data for future, larger clinical trials.
Main Methods:
- A prospective, single-arm clinical trial involving 24 women.
- A 4-week treatment period with escalating doses of gabapentin (300-900 mg/d).
- Data collection via patient-completed questionnaires.
Main Results:
- 16 women completed the trial; 4 discontinued due to side effects (light-headedness, dizziness).
- Significant reduction in hot flash frequency (66%) and hot flash score (70%) observed.
- Tendency for improvement in other reported symptoms among completers.
Conclusions:
- Gabapentin demonstrates potential as a treatment for hot flashes.
- Further investigation via double-blind, placebo-controlled trials is warranted.
- Gabapentin may be a suitable option for patients seeking non-hormonal hot flash management.